High Growth Tech Stocks To Watch In December 2024

As we approach the end of 2024, global markets have shown mixed signals with major U.S. stock indexes like the Nasdaq Composite experiencing moderate gains, although recent declines in consumer confidence and durable goods orders have raised concerns about economic stability. In this environment, high growth tech stocks are particularly intriguing due to their potential to capitalize on innovation and adaptability amidst fluctuating market conditions.

Top 10 High Growth Tech Companies

Name	Revenue Growth	Earnings Growth	Growth Rating
eWeLLLtd	26.41%	28.82%	★★★★★★
Waystream Holding	22.09%	113.25%	★★★★★★
Pharma Mar	25.43%	56.19%	★★★★★★
Sarepta Therapeutics	24.07%	43.17%	★★★★★★
CD Projekt	24.92%	27.00%	★★★★★★
TG Therapeutics	34.86%	56.98%	★★★★★★
Fine M-TecLTD	36.52%	131.08%	★★★★★★
Alkami Technology	21.99%	102.65%	★★★★★★
Elliptic Laboratories	70.09%	111.37%	★★★★★★
Travere Therapeutics	31.70%	72.51%	★★★★★★

Click here to see the full list of 1270 stocks from our High Growth Tech and AI Stocks screener.

Let's uncover some gems from our specialized screener.

Vitrolife (OM:VITR)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Vitrolife AB (publ) specializes in providing products for assisted reproduction and has a market capitalization of approximately SEK29.81 billion.

Operations: Vitrolife generates revenue through three primary segments: Genetics (SEK1.23 billion), Consumables (SEK1.61 billion), and Technologies (SEK721 million).

Vitrolife, amidst executive shifts and active conference participation, reported a slight dip in third-quarter net income to SEK 116 million from SEK 122 million year-over-year, despite a revenue increase to SEK 867 million. This scenario underscores a resilience in sales growth but highlights challenges in profit retention. The company's commitment to innovation is evident as it navigates through leadership transitions and strategic presentations at major healthcare conferences. With an expected annual revenue growth of 8.2%, Vitrolife is outpacing the Swedish market's growth of 1.2%, yet it faces hurdles to achieving profitability within three years—a testament to its potential tempered by immediate financial realities.

• Navigate through the intricacies of Vitrolife with our comprehensive health report here.

• Examine Vitrolife's past performance report to understand how it has performed in the past.

Jonhon Optronic Technology (SZSE:002179)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Jonhon Optronic Technology Co., Ltd. focuses on the research and development of optical, electrical, and fluid connection technologies and equipment in China, with a market cap of CN¥84.34 billion.

Operations: The company generates revenue primarily from its optical, electrical, and fluid connection technologies and equipment. It operates within China, leveraging its expertise in these specialized fields to drive business activities.

Jonhon Optronic Technology, amidst a name change and multiple corporate events, reported a revenue of CNY 14.1 billion for the nine months ending September 2024, down from CNY 15.36 billion year-over-year. Despite this dip, the company’s net income stood at CNY 2.51 billion compared to CNY 2.89 billion previously. These figures reflect resilience in maintaining substantial earnings despite revenue fluctuations. The firm's commitment to growth is underscored by its proactive shareholder engagements and strategic corporate adjustments aimed at refining its operational focus and market positioning.

• Unlock comprehensive insights into our analysis of Jonhon Optronic Technology stock in this health report.

• Assess Jonhon Optronic Technology's past performance with our detailed historical performance reports.

Broadex Technologies (SZSE:300548)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Broadex Technologies Co., Ltd. focuses on the research, development, production, and sale of integrated optoelectronic devices for optical communications both in China and internationally, with a market cap of CN¥13.10 billion.

Operations: The company engages in the development, production, and sale of integrated optoelectronic devices for optical communications. It operates both domestically in China and internationally.

Amidst a challenging fiscal period, Broadex Technologies demonstrated resilience with its latest earnings report, showing a revenue of CNY 1.23 billion for the nine months ending September 2024, slightly down from CNY 1.29 billion in the previous year. Despite this dip, the company's strategic maneuvers are evident in its recent acquisition by Ningbo Ningju Asset Management, enhancing shareholder value through significant equity changes. This move aligns with Broadex’s forward-looking approach as it aims to stabilize and expand amidst forecasts of annual revenue growth at an impressive rate of 24.3%. The firm’s commitment to innovation and market adaptation is further underscored by its expected transition into profitability within three years, supported by a robust forecasted earnings growth of 63.88% annually.

• Click here to discover the nuances of Broadex Technologies with our detailed analytical health report.

• Review our historical performance report to gain insights into Broadex Technologies''s past performance.

Seize The Opportunity

• Access the full spectrum of 1270 High Growth Tech and AI Stocks by clicking on this link.
• Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools.
• Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.

Searching for a Fresh Perspective?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com